ERBB2 and non-small cell lung carcinoma: This is the first prospective clinical study to demonstrate the curative effect and controllable safety of pyrotinib in NSCLC patients with HER2-amplified, limited by the absence of randomized controls and the absence of FISH validation of HER2-amplified status.